European equities closed sharply lower on Tuesday after disappointing data from the euro zone and increased concerns about tapering.» Read More
LONDON, Nov 12- An experimental GlaxoSmithKline drug, designed to fight heart disease in a new way, failed to meet its main goal in a major late-stage clinical study, dealing a blow to one of the company's biggest new treatment hopes.
LONDON, Nov 11- Cardiologists and shareholders in GlaxoSmithKline are about to learn if a big gamble on a new kind of heart medicine has paid off, with modest expectations creating a potentially big share price boost if the news is good.
Facing a decision on whether to impose tight restrictions on a booming market for electronic cigarettes, members of the European Parliament received a pleading letter in September that was signed by thousands of former smokers worried that "the positive story of e-cigarettes may be about to come to an abrupt halt."
Chinese President Xi Jinping was almost effusive as he welcomed an all-star group of global capitalists in Beijing two weeks ago. The FT reports.
WASHINGTON, Nov 4- In one of the largest health care fraud settlements in U.S. history, Johnson& Johnson will pay $2.2 billion to end civil and criminal investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses, U.S.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
*GSK's China sales plunged 61 percent in Q3. A charge against GSK itself would be a much more serious outcome for the company because it would imply higher-level corporate involvement and could result in major fines and even disruption to its operations in China.
LONDON, Oct 31- AstraZeneca promoted Marc Dunoyer to be its new chief financial officer on Thursday, plugging a gap in the British drugmaker's top management team as it grapples with falling sales and profits.
LONDON, Oct 30- Investors are buying European stocks that pay high dividends to make the most of an expected delay in the winding down of U.S. monetary stimulus and eventual interest rate hikes.
*Sales growth in China slows to 5 pct from 15 pct in Q2. PARIS, Oct 30- French drugmaker Sanofi lowered its 2013 profit guidance for a second time after a slowdown in China, weaker generic sales in Brazil and manufacturing problems at a Toronto vaccine plant dented third-quarter results.
French drugmaker Sanofi warned on its 2013 profit again as it reported lower-than-expected quarterly results.
RIO DE JANEIRO, Oct 28- Brazils top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.
LONDON, Oct 25- European regulators have recommended approval of Swiss firm Actelion's new pulmonary arterial hypertension drug Opsumit and a novel antidepressant called Brintellix from Denmark's Lundbeck.
European shares closed lower on Wednesday, hit by plans for new, tougher stress tests for euro zone banks from the European Central Bank.
U.S. stock index futures signaled a sharply lower open Wednesday, amid worries over financial conditions in China and as investors digested a mixed bag of corporate earnings.
*China sales slump 61 percent as doctors shun GSK products. LONDON, Oct 23- GlaxoSmithKline's drug sales in China slumped 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market products in the country and pushed some sales into the hands of rivals.
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
LONDON, Oct 23- GlaxoSmithKline's drug sales in China tumbled 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market medicines in the country.
Earnings reports from Boeing and dozens of other major companies could set the course for stocks Wednesday, as the Dow reaches for new highs.
Concerns that flu could mean an increase in staff sick days has prompted some companies to arrange flu jabs for their employees – boosting sales for some drugs companies.